Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZBIO ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisOptions ChainTrends About ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart Get ZBIO alerts:Sign Up Key Stats Today's Range$7.36▼$7.8550-Day Range$10.02▼$10.0952-Week Range$8.28▼$18.64Volume247,078 shsAverage Volume198,160 shsMarket Capitalization$320.11 millionAssets Under Management$2.85 millionDividend YieldN/ANet Expense Ratio0.95%Aggregate RatingN/A ETF OverviewZenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.Read More… ProShares UltraPro Short Nasdaq Biotechnology ExpensesTypeZBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.55%0.51%0.52%Other Expenses1.02%0.30%0.50%0.47%0.53%Total Expense1.77%0.70%0.72%0.67%0.71%Fee Waiver-0.82%-0.45%-0.51%-0.31%-0.56%Net Expense0.95%0.61%0.62%0.60%0.60% Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraPro Short Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO ETF News HeadlinesZenas BioPharma to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 28, 2025 | globenewswire.comZenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 12, 2024 | globenewswire.comHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?February 5, 2025 | Behind the Markets (Ad)Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)November 12, 2024 | globenewswire.comZenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesNovember 7, 2024 | globenewswire.comLast Week's 3 Biotech IPOs Prompt Huge Insider BuyingSeptember 22, 2024 | 247wallst.comSee More Headlines ZBIO ETF - Frequently Asked Questions How were ProShares UltraPro Short Nasdaq Biotechnology's earnings last quarter? ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) posted its earnings results on Tuesday, November, 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($13.00) by $7.98. When did ProShares UltraPro Short Nasdaq Biotechnology IPO? ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share. When does the company's lock-up period expire? ProShares UltraPro Short Nasdaq Biotechnology's lock-up period expires on Wednesday, March 12th. ProShares UltraPro Short Nasdaq Biotechnology had issued 13,235,294 shares in its initial public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. What other stocks do shareholders of ProShares UltraPro Short Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Short Nasdaq Biotechnology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Fund Details IssuerProShares Fund NameProShares UltraPro Short Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:ZBIO Inception Date6/22/2015 Fund ManagerMichael Neches, Tarak Dave Webwww.zenasbio.com Phone857-271-2954Fund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$2.85 million Average Daily Volume$25,501.70 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares41,790,000BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraPro Short Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraPro Short Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
